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Foreword T 
he International Wound Infection Institute (IWII) is an organisation of 
volunteer interdisciplinary health professionals dedicated to advancing 
and improving practice relating to prevention and control of wound 
infection. This includes acute wounds (surgical, traumatic and burns) 
and chronic wounds of all types, although principally chronic wounds of 
venous, arterial, diabetic and pressure aetiologies. 
Wound infection is a common complication of wounds. It leads to delays in wound 
healing and increases the risk of loss of limb and life. Implementation of effective 
strategies to prevent, diagnose and manage, is important in reducing mortality and 
morbidity rates associated with wound infection. 
This second edition of Wound Infection in Clinical Practice is an update of the first edition 
published in 2008 by the World Union of Wound Healing Societies (WUWHS). The 
original document was authored by leading experts in wound management and endorsed 
by the WUWHS. The intent of this edition is to provide a practical, updated resource that 
is easy-to-use and understand. 
For this edition, the IWII collaborative team has undertaken a comprehensive review of 
contemporary literature, including systematic reviews and meta-analyses when available. 
In addition, the team conducted a formal Delphi process to reach consensus on wound 
infection issues for which scientific research is minimal or lacking. This rigorous process 
provides an update on the science and expert opinion regarding prevention, diagnosis 
and control of wound infection. This edition outlines new definitions relevant to wound 
infection, presents new paradigms and advancements in the management and diagnosis 
of a wound infection, and highlights controversial areas of discussion. 
We hope this updated resource will guide your clinical practice and will serve as an 
informative resource for the education of other health professionals, as well as individuals 
with, or at risk of, wound infection. 
Terry Swanson, NPWM 
Project Chair 
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Principles of best practice 
T 
his update provides an opportunity to explore contemporary advances 
in wound infection knowledge and practice. Since 2008, scientific 
and clinical understanding of chronic wound infection has developed 
significantly.1-3 In particular, awareness of the presence and impact of 
wound biofilm has advanced enormously; however, understanding of 
its pathogenesis is yet to be clarified fully4-8. A holistic approach to individuals with, 
or at risk of, active wound infection remains essential to best practice in prevention, 
identification and management of wound infection. This is of particular importance in 
the context of increasing antibiotic resistance. 
This update is the result of a comprehensive literature review that identified relevant 
contemporary evidence, together with a formal Delphi process to establish expert 
consensus on topics where scientific evidence is lacking. The full methodology is outlined 
in Appendix 1. Key updates appraised in this edition include: 
n The wound infection continuum 
n Definitions related to wound chronicity 
n Identification and diagnosis of wound infection 
n Topical and systemic management of wound infection using a holistic approach. 
The primary determinants of the pathological process through which presence of 
bacteria and other microorganisms results in wound infection and harmful effects on an 
individual with, or at risk of, a wound remains the same. These primary factors can be 
briefly outlined as: 
n The ability of the immune system to combat potential pathogens (host defence)9-11 
n The number of microbes in the wound. A greater number of microbes can overwhelm 
host defences11 
n The species of bacteria or microbe present. Some microbes have greater capacity to 
produce a detrimental effect in low numbers (virulence) and some are able to form and 
reform biofilm more rapidly.12, 13 
 
 
PRACTICE POINT 
P  The effectiveness of the host’s defence system, together with the quantity and virulence of microbes, influences the development of wound infection 
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“A holistic approach to 
individuals with, or at risk 
of, active wound infection 
remains essential to best 
practice in prevention, 
identification and 
management of wound 
infection. This is of particular 
importance in the context 
of increasing antibiotic 
resistance.” 
DEFINITIONS 
International debate regarding the wound infection continuum and definitions associated 
with wound infection is ongoing. A persistent area of contention has been identification 
of the point at which management of wound infection should commence, particularly 
for wounds that do not exhibit the classic signs and symptoms associated with 
wound infection. 
Through three rounds of Delphi voting, the IWII expert authors agreed on the following: 
n Critical colonisation should be removed from the wound infection continuum due to the 
lack of a specific definition or unanimous understanding of the term 
n The term ‘microbes’ should replace ‘bacteria’ in the wound infection continuum, given the 
understanding that organisms other than bacteria (e.g. fungi) are common causatives of 
wound infection 
n Presence of biofilm should be added to the wound infection continuum 
n Definitions for acute and chronic wounds. 
 
The IWII experts reached agreement on the following definitions: 
Acute wound: a wound with an aetiology that occurs suddenly, either with or without 
intention, but then heals in a timely manner. 
Chronic wound: a wound that has a slow progression through the healing phases, or 
shows delayed, interrupted or stalled healing due to intrinsic and extrinsic factors 
that impact on the individual and their wound. A chronic, non-healing wound could be 
suggestive of a biofilm, providing holistic evaluation has excluded or corrected underlying 
pathologies such as ischaemia. 
Biofilm: a structured community of microbes with genetic diversity and variable gene 
expression (phenotype) that creates behaviours and defences used to produce unique 
infections (chronic infection). Biofilms are characterised by significant tolerance to 
antibiotics and biocides while remaining protected from host immunity. 
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The wound infection continuum 
 
ound infection is the invasion of a wound by proliferating 
microorganisms to a level that invokes a local and/or systemic 
response in the host. The presence of microorganisms within 
the wound causes local tissue damage and impedes wound 
healing.3, 11 Intervention is generally required to assist host 
defences in destroying the invading microorganisms.3 The wound infection continuum 
provides a framework through which the impact microbes have on a wound and 
wound healing can be conceptualised (Figure 1). 
STAGES IN THE WOUND INFECTION CONTINUUM 
The relationship between the host, the wound and microorganisms in the development of 
wound infection has been well described in the literature. However, the concept of wound 
microbial balance and the progression from a state of wound contamination to systemic 
infection is yet to be established fully. 
It is well acknowledged that it is more than the presence of bacteria that leads to adverse 
events in wounds. The wound infection continuum has been updated to reflect that 
microbes other than bacteria are associated with wound infection, and microbial virulence 
(as well as numbers) contributes to the development of wound infection.2, 3, 11, 14-16 The stages 
in the wound infection continuum describe the gradual increase in the number and virulence 
of microorganisms, together with the response they invoke within the host (Figure 1).3 
Contamination 
Wound contamination is the presence of non-proliferating microbes within a wound at a 
level that does not evoke a host response.2, 3 Virtually from the time of wounding, all open 
wounds are contaminated with microbes. Chronic wounds become contaminated from 
endogenous secretions (i.e. natural flora) and exogenous microbial sources, including 
poor hand hygiene practised by healthcare clinicians and environmental exposure.17 
Unless compromised, the host defences respond swiftly to destroy bacteria through a 
process called phagocytosis.18 
Colonisation 
Colonisation refers to the presence within the wound of microbial organisms that undergo 
limited proliferation without evoking a host reaction.3, 11 Microbial growth 
occurs at a non-critical level, and wound healing is not impeded or delayed.18, 19 Sources 
for microorganisms may be natural flora, exogenous sources or as a result of 
environmental  exposure. 
Local infection 
Wound infection occurs when bacteria or other microbes move deeper into the wound 
tissue and proliferate at a rate that invokes a response in the host.2, 11 Local infection 
is contained in one location, system or structure. Especially in chronic wounds, local 
wound infection often presents as subtle signs that can be considered covert signs of 
infection20, 21 that may develop into the classic, overt signs of infection. This is discussed 
in more detail opposite and in Table 1. 
Spreading infection 
Spreading infection describes the invasion of the surrounding tissue by infective 
organisms that have spread from a wound. Microorganisms proliferate and spread, to 
PRACTICE POINT 
P  
Box 1: Advances in 
terminology 
The term ‘critical 
colonisation’ has been a 
topic of debate since it was 
first proposed in 1998 as 
a concept describing the 
identification of wound 
infection through clinical 
observation rather than 
microbial confirmation.1 
Several terms are 
synonymous with critical 
colonisation, including local 
infection, topical infection 
and covert infection. 
Regardless of the term 
used, it is now generally 
accepted that a wound with 
microbial imbalance exhibits 
subtle signs and symptoms 
that can be observed by 
experienced clinicians.2, 3 
These covert signs of local 
infection are often apparent 
before the wound exhibits 
classic (overt) signs and 
symptoms. 
Wound infection 
is the presence 
of microbes in 
sufficient numbers 
or virulence to 
cause a host 
response locally 
and or systemically 
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a degree that signs and symptoms extend beyond the wound border.22, 23 Spreading 
infection may involve deep tissue, muscle, fascia, organs or body cavities. 
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Systemic infection 
Systemic infection from a wound affects the body as a whole,22 with microorganisms spreading 
throughout the body via the vascular or lymphatic systems. Systemic inflammatory response, 
sepsis and organ dysfunction are signs of systemic infection.23 
In the development of this update, the IWII experts agreed that the display of covert signs of 
infection is an early stage of local infection, and does not represent a distinctly different phase in 
the wound infection continuum. Thus, the term ‘critical colonisation’, which has previously been 
poorly defined, has been removed from the continuum in this update (Box 1). 
Table 1 provides detailed information regarding the signs and symptoms commonly exhibited by 
the individual and the wound as infection emerges and proliferates. This includes the distinction 
between covert and overt local infection. 
 
Figure 1 | IWII wound infection continuum22, 24, 25 
 
 
 
No antimicrobials indicated Topical antimicrobial Systemic and topical antimicrobials 
 
 
 
 
 
Table 1: Signs and symptoms associated with stages of the wound infection continuum 
Contamination26 Colonisation26 Local infection Spreading infection22, 23 Systemic infection22, 23 
All wounds may 
acquire micro- 
organisms. If suitable 
nutritive and physical 
conditions are not 
available for each 
microbial species, or 
they are not able to 
successfully evade host 
defences, they will not 
multiply or persist; 
their presence is 
therefore only transient 
and wound healing is 
not delayed 
Microbial 
species 
successfully 
grow and 
divide, but 
do not cause 
damage to 
the host or 
initiate wound 
infection 
Covert (subtle) signs of local 
infection:2,  27-36 
n Hypergranulation 
(excessive ‘vascular’ 
tissue) 
n Bleeding, friable 
granulation 
n Epithelial bridging and 
pocketing in granulation 
tissue 
n Wound breakdown and 
enlargement 
n Delayed wound healing 
beyond expectations 
n New or increasing pain 
n Increasing malodour 
Overt (classic) signs 
of local infection:2, 27, 
28, 35, 36 
n Erythema 
n Local warmth 
n Swelling 
n Purulent discharge 
n Delayed wound 
healing beyond 
expectations 
n New or increasing 
pain 
n Increasing 
malodour 
n Extending in 
duration 
+/- erythema 
n Lymphangitis 
n Crepitus 
n Wound 
breakdown/ 
dehiscence with 
or without satellite 
lesions 
n Malaise/ 
lethargy or non- 
specific general 
deterioration 
n Loss of appetite 
n Inflammation, 
swelling of lymph 
glands 
n Severe sepsis 
n Septic shock 
n Organ failure 
n Death 
Colonisation Local infection Spreading infection 
Vigilance required Intervention required 
Contamination 
 
Systematic infection 
BIOFILM 
Increasing microbial virulence and/or 
numbers 
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Biofilm in the wound 
 
he wound infection continuum has been updated to include biofilm. 
Early research has provided evidence regarding biofilms and the disease 
concept.37, 38 The seminal work of three studies published in 2008 confirmed 
that biofilms develop in wounds.4, 6, 14 Using scanning electron microscopy, in 
2008 James et al, via a prospective study, established that 60% of chronic 
wounds contained biofilm, compared to 6% of acute wounds.4 Since then, a rapidly 
expanding body of scientific literature has described the impact of biofilm on a wound. 
The growing understanding and acceptance of the role of biofilm in wound infection has 
led to evolution in clinical management of the chronic, non-healing wound that seeks to 
address potential presence of biofilm.39, 40 Revision of the wound infection continuum 
highlights the significant progression of both scientific knowledge and clinical practice 
with respect to understanding and managing wound biofilm. 
BIOFILM CYCLE 
Despite significant advances, emerging science from the laboratory has yet to provide us 
with a full understanding of wound biofilm in the clinical context. However, biofilm- 
associated complications that increase the risk of morbidity and mortality warrant 
emphasis on wound bed preparation41 that incorporates the principles of biofilm-based 
wound care (BBWC).23, 42-44 Treatment strategies should be based on the cycle of biofilm38, 45 
(Figure 2), and aim to prevent attachment, interrupt quorum sensing and planktonic 
phenotypic changes, and to prevent or delay re-formation of biofilm. 
Figure 2 illustrates the cycle of biofilm formation, maturation and dispersal. Based on in 
vitro research the stages in the biofilm cycle are briefly described: 
Planktonic 
In the planktonic phase, free-floating, non-attached single microbes attach to a surface 
or each other. In this early phase, the attachment is weak and reversible. The attachment 
is mediated by pili, flagella or other surface appendages or specific receptors.46, 47 
Most antimicrobial treatments are based on disrupting or killing microbes during the 
planktonic phase. 
Irreversible attachment 
If single microbes that are anchored together or to a surface are not separated, the 
attachments made via pili, flagella and other appendages become stronger and 
irreversible. Attachment of microbes is mediated by the secretions of the extracellular 
polymeric substance (EPS). The EPS surrounds the growing colony and acts as a 
protective barrier against the host immune response.47 
Cell proliferation 
After attachments become strong and irreversible, microbe cells begin proliferating 
via a mechanism called quorum sensing (a process by which bacteria can regulate and 
respond to fluctuations in cell population density).48 When quorum-sensing molecules are 
secreted, other microbes become attracted to, and join, the biofilm colony.47 This process 
results in formation of micro-colonies. 
Growth and maturation 
The biofilm grows and differentiates, culminating in a mature biofilm community 
INTERNATIONAL CONSENSUS UPDATE 2016 | WOUND INFECTION IN CLINICAL PRACTICE 
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with structural features such as water channels and towering clusters of cells. The 
host’s defences are inadequate to eradicate the biofilm, but recognise its presence 
with inappropriate over-recruitment of neutrophils, pro-inflammatory cytokines and 
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Figure 2 | Biofilm cycle 
(Adapted from Stoodley et al, 
200238 and Clinton and Carter, 
2015.45 Reprinted with permission) 
 
 
 
 
excessive host-derived proteases. This leads to tissue destruction and increased capillary 
permeability which, in turn, provides nutrition for the biofilm.47 Once biofilm is in the 
mature state, it is postulated that normal wound management strategies are less effective. 
Dispersal 
Mature biofilm begins reseeding the wound surface with planktonic microbes as either 
a passive or active dispersal process. Abundant nutrition is suggested as one trigger for 
passive dispersal.47, 49 
IDENTIFYING BIOFILM IN A WOUND 
The identification of biofilm in a wound via visual indicators has been a recent area of 
debate.23 Some commentary has suggested that ‘foreign’ material (e.g. fibrin, necrosis, 
slimy surface substance) on a wound surface represents biofilm.50, 51 However, research on 
wound samples indicates that, while biofilm may account for the visible appearance of some 
wounds, it is not a conclusive indicator. 
Further, many wounds that appear to be healthy to the naked eye are shown via laboratory 
investigation to have biofilm present that contributes to stalled healing.52 Biofilm can form 
deep in wound tissue where it is impossible to identify visually.5, 53 Further research is 
required for this particular aspect of biofilm identification, and research on identification of 
signs and symptoms of biofilm continues in laboratory and clinical fields.51 Box 2 outlines the 
criteria indicative of a potential biofilm. 
 
PRACTICE POINT 
P  
Biofilm cannot be 
directly visualised 
in a wound. The 
experienced 
clinician may 
suspect biofilm is 
present through 
observation of 
indicative wound 
characteristics 
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Box 1: Criteria indicative of potential biofilm 
 
n Failure of appropriate antibiotic treatment 
n Recalcitrance to appropriate antimicrobial treatment 
n Recurrence of delayed healing on cessation of antibiotic treatment 
n Delayed healing despite optimal wound management and health support 
n  Increased exudate/moisture 
n Low-level chronic inflammation 
n Low-level erythema 
n Poor granulation/friable hypergranulation 
n Secondary signs of infection 
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Diagnosis of wound infection 
 
nderstanding the risk factors, and the signs and symptoms of wound 
infection is imperative for health professionals. The presumptive 
diagnosis of wound infection is principally based on the clinician’s 
assessment of the individual (host), the wound and periwound 
tissue, and host responses such as systemic inflammatory response 
or sepsis. Comprehensive assessment for wound infection aids early detection 
and timely treatment. 
RISK OF INFECTION 
Characteristics of both the individual, their wound and the wound environment can 
contribute to the development of infection in a wound. The type of wound (i.e. acute or 
chronic) contributes to infection risk, and a variety of additional factors associated with 
the operative procedure increase the risk for infection in surgical wounds.54, 55 
In most cases, development of wound infection is multifactorial and occurs when 
cumulative risk factors overwhelm the host’s defence system.55 Table 2 outlines factors 
that are associated with an increased risk of wound infection. 
 
Table 2: Factors associated with increased risk of wound infection 
Characteristics of the individual21, 40, 41, 56-60 21, 40, 41, 54, 55, 58, 61-66 
n Poorly controlled diabetes 
n Prior surgery 
n Radiation therapy or chemotherapy 
n Conditions associated with hypoxia and/or poor tissue perfusion (e.g. anaemia, cardiac or respiratory disease, arterial or vascular disease, 
renal impairment, rheumatoid arthritis, shock) 
n Immune system disorders (e.g. acquired immune deficiency syndrome, malignancy) 
n  Inappropriate antibiotic prophylaxis, particularly in acute wounding 
n Protein-energy malnutrition 
n Alcohol, smoking and drug abuse 
Characteristics of the wound21, 40, 54, 55 
Acute wounds 
n Contaminated or dirty wounds 
n Trauma with delayed treatment 
n Pre-existing infection or sepsis 
n Spillage from gastro-intestinal tract 
n Penetrating wounds over 4 hours 
n Inappropriate hair removal 
n Operative factors (e.g. long surgical 
procedure, hypothermia, blood transfusion) 
Chronic wounds 
n Degree of chronicity/duration of wound 
n Large wound area 
n Deep wound 
n Anatomically located near a site of potential 
contamination (e.g. perineum or sacrum) 
Both wound types 
n Foreign body (e.g. drains, sutures) 
n Haematoma 
n Necrotic wound tissue 
n Impaired tissue perfusion 
n Increased exudate or moisture 
Characteristics of the environment21, 40, 66 
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n Hospitalisation (due to increased risk of exposure to antibiotic resistant organisms) 
n Poor hand hygiene and aseptic technique 
n Unhygienic environment (e.g. dust, unclean surfaces, mould/mildew in bathrooms) 
n Inadequate management of moisture, exudate and oedema 
n Inadequate pressure off-loading 
n  Repeated trauma (e.g. inappropriate dressing removal technique) 
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SIGNS AND SYMPTOMS OF WOUND INFECTION 
Characteristics of both the individual, their wound and the wound environment can 
contribute to the development of infection in a wound. The type of wound (i.e. acute or 
chronic) contributes to infection risk, and a variety of additional factors associated with 
the operative procedure increase the risk for infection in surgical wounds.54, 55 In most 
cases, development of wound infection is multifactorial and occurs when cumulative risk 
factors overwhelm the host’s defence system.55 Table 2 (page 10) outlines factors that are 
associated with an increased risk of wound infection. 
Infection in acute wounds (including surgical/traumatic wounds and burns) in otherwise healthy 
individuals is usually obvious to an experienced clinician. Individuals present with classic (overt) 
signs and symptoms of wound infection (Table 1, page 8).23 However, in immunocompromised 
individuals and those with chronic wounds, early detection of infection relies on identification of 
subtle or covert signs of infection. Covert signs of wound infection include:2, 27-36 
n Friable, bright red granulation tissue 
n Increasing malodour 
n New or increased pain or change in sensation 
n Epithelial bridging and pocketing in granulation tissue 
n Delayed wound healing beyond expectations 
n Wound breakdown and enlargement or new ulcerations of the peri-wound (satellite lesions). 
Clinicians need to act promptly if an individual with a wound demonstrates signs of potentially 
fatal infection, including systemic inflammatory response, sepsis, extensive tissue necrosis, gas 
gangrene or necrotising fasciitis. 
Scoring systems and diagnostic criteria have been developed to assist in the identification 
of infection in specific types of acute wounds. For example, the ASEPSIS67 scoring system is 
validated for assessing surgical site infection in sternal wounds.68 The Centers for Disease 
Control and Prevention have developed definitions for wound infection; however, they are 
limited to types of surgical site infection.69 Validated scoring systems to aid diagnosis of wound 
infection in chronic wounds have not yet been developed. If a wound infection scoring system is 
used to aid diagnosis, it should be reliable and valid for the type of wound being assessed.68 
INVESTIGATIONS TO DIAGNOSE WOUND INFECTION 
Clinical assessment can be supplemented with microbiological investigation, blood tests and/or 
imaging to: 
n Establish specific pathogen strains in the wound 
n Confirm the microbes are sensitive to the type of antibiotics commenced or to be prescribed 
n Identify any possible complications 
n  Guide management strategies. 
Microbiology 
Microbiological investigations depend on the availability of local services. Microbiology 
should not be undertaken routinely or without substantial cause.70-72 Indications for 
undertaking microbiological analysis are provided in Box 3. 
 
* In individuals showing signs of sepsis, blood cultures are also indicated, and other likely sites of infection should be considered for sampling 
‡ In patients with compromised immune competency (e.g. those taking immunosuppressants or corticosteroids, or with diabetes mellitus or 
arterial peripheral disease), consider sampling chronic wounds with signs of local wound infection and/or delayed healing 
Box 2: Indications for wound specimen collection for standard microbiological analysis22, 72 
 
n Acute wounds with classic signs and symptoms of infection 
n Chronic wounds with signs of spreading or systemic* infection‡ 
n Infected wounds that have failed to respond to antimicrobial intervention, or are 
deteriorating despite appropriate antimicrobial treatment 
n In compliance with local protocols for the surveillance of drug-resistant 
microbial species 
n Wounds where the presence of certain species would negate a surgical 
procedure (e.g. beta haemolytic streptococci in wounds prior to skin grafting) 
PRACTICE POINT 
P  
Do not undertake 
microbiological 
analysis of wound 
specimens in 
the absence of 
an appropriate 
indication 
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Sampling techniques to obtain a specimen for microbiological analysis include wound 
culture or swabbing the wound bed, needle aspiration and tissue biopsy. Where pus is 
present it should be collected directly by syringe or swab. 
Despite being the most widely used technique for microbial monitoring, wound culture 
may not distinguish between colonisation and wound infection.73 Unequal distribution of 
pathogens in wounds has been demonstrated,5 and this can influence the effectiveness of a 
wound swab in attaining a microbial specimen. Although definitive studies on the optimum 
method of sample collection have not yet been performed, several studies suggest that the 
Levine technique (Table 3) is more effective than the Z-swab technique.73-75 
 
 
The literature suggests that wound biopsies are recommended for wounds with antibiotic- 
resistant species and to determine the effect of antimicrobial intervention. In clinical 
practice, wound biopsies are rarely performed on a routine basis73 due to cost, access to 
services and discomfort to the individual.76 
All wound samples should be transported to the microbiology laboratory for processing 
within 4 hours, accompanied by full clinical details to ensure that appropriate testing is 
performed. Documentation accompanying the wound sample should include:77 
 
n Details about the wound (e.g. anatomical location, duration and aetiology) 
n Details about the individual (e.g. demographics and significant contributing comorbidities) 
n Clinical indication for the wound sample (e.g. signs and symptoms and suspected microbes) 
n Current or recent antibiotic use. 
 
Quantitative analysis is not routinely available. Characterisation of microbial flora takes at 
least 24 hours (longer for anaerobes, mycobacteria and fungi). When rapid investigation 
is required (e.g. in cases of sepsis) a blood culture may yield results within 4 hours, or 
microscopic examination of specimens by more specialised laboratory staff may guide 
Table 3: Levine technique 
Step Action Further information 
1 Cleanse and n Inform and seek permission from patient to obtain specimen 
 
debride wound n Cleanse wound using warm normal saline 
 
prior to wound n Debride non-viable tissue as required 
 
culture n Cleanse wound again 
2 Moisten culture tip n Moisten culture tip with sterile normal saline, especially with dry wounds 
3 Where to obtain 
specimen 
n 
n 
Obtain specimen from cleanest area in the wound 
Where possible, do not obtain from slough or necrotic tissue 
4 Technique n Inform the patient that procedure may cause discomfort 
  
n Place wound culture into wound 
  
n Firmly press swab into wound and rotate 
  
n Using a sterile technique, place swab into culture container 
5 Label appropriately n Patient label on culture container and pathology slip 
  
n Provide site, time and initials of who obtained specimen (e.g. left medial distal 
   
malleolus wound) 
  
n Provide as much relevant history as appropriate: 
  
n Current antibiotic or medication (steroid) 
  
n Comorbidity (DM) 
  
n Specific microbe suspected (Pseudomonas aeruginosa) 
  
n Provisional diagnosis of wound 
  
n Duration of wound 
6 Apply dressing as 
appropriate 
n 
n 
Medicated dressings may be appropriate 
Moisture management and wound bed preparation principles should be adhered to 
 
It is important to 
recover species 
at and below the 
wound surface, 
therefore wound 
cleansing and 
debridement (if 
necessary) without 
antimicrobials 
should be 
completed before 
sampling when 
using the Levine 
technique 
PRACTICE POINT 
P  
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antimicrobial therapy faster. 
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EMERGING  DIAGNOSTIC TECHNIQUES 
Standard clinical microbiology laboratory results only provide information about a small 
percentage of the total bacterial species that are present, particularly in chronic wounds.77 
Testing for fungi and anaerobic bacteria requires additional investigations and processing. 
If sensitivities are provided, less experienced clinicians may feel the need to commence 
antibiotics without considering the clinical indications. Clinicians should be wary 
of interpreting a microbiology report in isolation. Consider the report in the context 
of the individual, their wound and your clinical judgement. If appropriate, consult a 
microbiologist or an infectious disease expert. 
Since many microorganisms are difficult to culture by standard techniques, strategies to 
characterise genetic markers of microbial species using molecular techniques have been 
developed in specialist facilities.78-80 These molecular techniques, some of which are used 
to identify biofilm in a wound,81-83 are summarised in Table 4. 
 
Table 4: Types of microscopy81-83   
Type of microscopy Mechanism Limit of 
resolution 
(maximum 
magnification) 
Advantages Disadvantages 
Light microscopy Visible light 0.2 µm (1500x) n Mostly used on isolated cultures or 
sections of tissue 
n Gram stain used to establish 
presumptive identification of 
species 
n Low-cost and readily available 
n Impossible to obtain 
definitive identification of 
microbial species 
n Cannot identify biofilm 
Fluorescence 
microscopy 
(FISH) 
Ultraviolet light 0.1 µm (2000x) n With fluorescent dyes/labels, 
species can be identified and their 
relative locations mapped 
n Can identify biofilm 
n Use limited to microbial 
cell suspensions and thin 
tissue sections 
n Cost of specific dyes and 
probes 
n Only fluorescent structures 
observed 
Confocal laser scanning 
microscopy (CLSM) 
A laser beam 
coupled to a light 
microscope 
0.1 µm (2000x) n With fluorescent dyes/labels, 
species can be identified and their 
relative locations mapped 
n Tissue blocks can be examined 
and images obtained at regular 
depths can be reconstructed to 
generate 2D or 3D structure of the 
whole specimen 
n Can identify biofilm 
n Cost of equipment and 
technical support 
n Cost of specific dyes and 
probes 
n Fluorescence decays 
relatively quickly 
n Only fluorescent structures 
are observed 
Scanning electron 
microscopy (SEM) 
Electrons are 
beamed onto the 
specimen from an 
angle and deflected 
electrons are 
collected 
10 µm 
(500,000x) 
n Minimal sample preparation time 
n Images of the surface layers of 
specimens provide insight into 
3D structure 
n Can identify biofilm 
n Cannot examine living 
material 
n Dehydration of samples 
may cause changes 
n Cost of equipment and 
technical support 
Transmission electron 
microscopy (TEM) 
Electrons are 
beamed through a 
thin section of the 
specimen 
0.2 µm 
(5,000,000x) 
n Images provide detailed 
information on internal cellular 
structures 
n Can identify biofilm84 
n Cannot examine living 
material 
n Specimen preparation is 
lengthy, and may introduce 
artefacts 
n Cost of equipment and 
technical support 
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In addition, use of DNA sequencing techniques that can more precisely identify species 
of microbes in a wound specimen is rapidly advancing, including microbes not identified 
by culture-based techniques. Samples of genetic material from a biofilm are obtained 
and a universal barcode marker is amplified using polymerase chain reaction, a technique 
that creates multiple copies of the organism’s DNA sequence.85 These DNA samples are 
analysed and compared with a database of existing DNA sequences to identify all of the 
microbial species involved in wound infection85 and to inform the selection of strategies 
to manage biofilm.86 In the future, DNA sequencing will likely have a greater role in 
diagnostics.87,  88 
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Holistic management 
 
 
Characteristics of both the individual, their wound and the wound environment 
can contribute to the development of infection in a wound. The type of wound (i.e. 
acute or chronic) contributes to infection risk, and a variety of additional factors 
associated with the operative procedure increase the risk for infection in surgical 
wounds.54, 55 
In most cases, development of wound infection is multifactorial and occurs when 
cumulative risk factors overwhelm the host’s defence system.55 Table 2 (page 10) 
outlines factors that are associated with an increased risk of wound infection. 
A holistic approach is essential to diagnose and treat wound infection accurately. Effective 
management of a wound infection in the light of co-morbidities and subsequent wound 
healing requires an interdisciplinary team approach.89 The goal of patient-centred care is 
to readjust the interaction between the individual and the infecting pathogen in favour of 
the individual by: 
n Optimising the host response 
n Reducing the number or virulence of microorganisms in the wound 
n Optimising the wound healing environment. 
 
OPTIMISING HOST RESPONSE 
Measures to optimise the host response attempt to maximise healing potential by 
enhancing the ability of the individual to resist infection. This includes addressing systemic 
and/or intrinsic factors that may have contributed to the development of the wound 
infection (e.g. optimisation of glycaemic control and the use of disease-modifying drugs in 
rheumatoid  arthritis).90-92 
 
Factors that contribute to wound infection are often the same factors that contributed to 
the development of the initial wound. Local moisture management, pressure offloading 
and oedema control are recognised as important interventions for maximising the wound 
healing environment and decreasing biofilm nutrition.93 
 
INFECTION CONTROL IN WOUND CARE 
To prevent further contamination and cross infection, it is important to maintain an aseptic 
non-touch technique when managing the wound. Performing the aseptic technique during 
relevant clinical procedures (e.g. changing the wound dressing) protects the individual by 
reducing exposure to pathogenic microorganisms. Aseptic technique also reduces the risk 
of cross infection. 
A risk assessment should be conducted prior to performing wound management 
procedures. If it is necessary to touch any area of the wound directly, sterile gloves and 
equipment are required. Asepsis is supported by standard precautions, including:94 
n Practising regular and effective hand hygiene 
n Appropriate use of sterile and non-sterile gloves 
n Use of personal protective equipment (e.g. mask and gown) 
PRACTICE POINT 
P  
Implement local 
infection control 
policies and 
procedures 
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n Conducting wound care in a clean environment 
n Strategic sequencing of care 
n  Sharps management 
n  Environmental controls. 
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EFFECTIVE MANAGEMENT OF WOUND INFECTION 
Effective wound management requires holistic assessment of the individual, their wound 
and the wound care environment to promote host defence and response to infection. 
For individuals with significant and life-threatening infection (e.g. sepsis), admission to a 
higher level of monitoring/care and with immediate resuscitation with fluids, oxygen and 
antibiotics is imperative. Management strategies for individuals with, or at risk of, wound 
infection is summarised in Figure 3. 
 
 
 
  
Reduce wound 
microbial load 
n Prevent cross infection by 
implementing universal 
precautions and aseptic 
technique 
n Facilitate wound drainage 
n Ensure peri-wound hygiene 
and protection 
n Manage wound exudate 
n Optimise the wound bed: 
– Remove necrotic tissue, 
debris, foreign bodies, 
wound dressing remnants 
and slough 
– Disrupt biofilm by 
debriding 
– Cleanse the wound with 
each dressing change 
n Use appropriate dressings to 
manage exudate – a dressing 
containing an antimicrobial 
may be considered 
n If deemed necessary, 
consider an appropriate 
topical antiseptic for a 
short period for time 
(e.g. 2 weeks) 
Optimise individual host 
response 
n Optimise management of 
comorbidities (e.g. diabetes, 
tissue perfusion/oxygenation) 
n Minimise or eliminate risk 
factors that increase infection 
risk where feasible 
n Optimise nutritional status and 
hydration 
n Assess and manage other 
anatomical sites of infection 
(e.g. urinary tract, chest) 
n Treat systemic symptoms (e.g. 
pain, pyrexia) 
n Promote psychosocial support 
n Provide appropriate systemic 
antimicrobial therapy 
n Ensure the individual is 
engaged in development of an 
personalised  management plan 
n Promote education by the 
interdisciplinary wound 
management team to the 
individual and their caregivers 
Individuals with 
severe sepsis 
require immediate, 
high-level 
resuscitation with 
fluids, oxygen and 
systemic antibiotic 
therapy 
EFFECTIVE  WOUND  INFECTION MANAGEMENT 
PRACTICE POINT 
P  
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Figure 3 | Effective 
management of 
wound  infection95 
Regular  reassessment 
n Diagnostic interpretation requires holistic 
knowledge of the individual and their wound 
n Evaluate interventions based on efficacy 
in resolving signs and symptoms of wound 
infection and the overall condition of the 
individual. Consider the following: 
– Has the individual’s pain decreased? 
– Has exudate decreased? 
– Has malodour resolved? 
– Has erythema and oedema decreased? 
– Is there a reduction in non-viable tissue? 
– Is the wound reducing in size and/or depth? 
n Monitor condition of the peri-wound, 
particularly in heavily exuding wounds 
n If there is limited or no improvement in signs 
and symptoms of wound infection, reassess 
the individual and their wound and adjust the 
management plan 
n Consider if further investigations are required 
n Consider referring the individual to 
specialised services (e.g. a wound clinic) 
n Document wound assessments (e.g. serial 
digital photography) 
Promote environmental 
and general measures 
n Perform wound care 
in a clean environment 
n Determine that the 
appropriate aseptic 
technique required 
is based on risk 
assessment of the 
patient, the wound 
and the environment 
n Store equipment and 
supplies appropriately 
n Provide education 
for the individual and 
their caregivers 
n Regularly review 
local policies and 
procedures 
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Wound bed preparation 
ecrotic, non-viable tissue provides a focus for infection, exacerbates 
the inflammatory response and impedes wound healing.12 This includes 
foreign material (wound dressing remnants, multiple organism-related 
biofilm or slough, exudate and debris) on the wound bed. The principles 
of wound bed preparation are the entrenched concepts, which also 
include the acronyms TIME (Tissue; Infection/Inflammation; Moisture; Edge)23, 96 and 
Biofilm-based Wound Care (BBWC).97 These principles promote maintenance of a 
healthy wound bed through therapeutic wound cleansing, disruption of biofilm and 
removal of necrotic, non-viable tissue through wound debridement. 
DEBRIDEMENT 
To stimulate wound healing and manage bioburden there are a number of methods 
of debridement (see Table 5). It has been demonstrated that debridement provides a 
window of opportunity in which the biofilm defences are temporarily interrupted, allowing 
increased efficacy of topical and systemic management strategies.13 Further research 
is required to establish the optimal frequency of debridement; however, expert opinion 
suggests that debridement should be performed at least weekly. To disrupt biofilm 
attachment and prevent dispersal, use a combination of debridement strategies together 
with therapeutic cleansing with topical antiseptics and application of antimicrobial wound 
therapy dressings.12, 98 New, effective biofilm disruptors that do not contain antiseptic may 
offer an alternative to antiseptic-containing therapies. 
 
Table 5: Types of debridement 
Type of debridement Method Effect on biofilm 
Surgical Performed in the operating room using scalpel 
and scissors91, 99 
n Disrupts biofilm and removes foci of infection99 
n If all tissue is removed, deeper biofilm can be disrupted99 
Conservative/sharp Performed using aseptic technique with sterile 
curette, scalpel and scissors91, 99 
Removes and disrupts superficial biofilm99 
Autolytic Selective, slow debridement that occurs 
naturally and can be aided by using topical 
agents and contemporary wound dressings, 
including:91,  99 
n Cadexomer iodine 
n Honey 
n Fibre gelling wound dressings 
n Polyhexamethylene biguanide (PHMB) 
Varying efficacy on biofilm depending on the product and the phase of the 
biofilm cycle in which it is applied99 
Mechanical Non-selective debridement performed using:99 
n Therapeutic irrigation (4 to 15 psi) 
n Monofilament fibre pads 
n Low-frequency ultrasound 
n Hydrosurgery 
Some levels of disruption and removal of biofilm99 
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Enzymatic/ 
chemical/surfactant 
Application of exogenous enzymes or 
chemicals to the wound surface, including:99 
n Alginogel 
n Enzymatic debriders 
n Wound cleaners and gels with high or low 
concentrations of surfactant 
Some levels of disruption and removal of biofilm99, 106 
Biosurgical/ 
larval therapy 
Sterile fly larvae that produce a mixture of 
proteolytic enzymes91, 100, 101 
Good evidence of removal of biofilm in vitro100, 101 
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The impact of the different types of debridement on biofilm is dependent upon its stage 
in the life cycle. Clinicians should be aware of the efficacy of different debridement 
strategies and therapeutic topical agents on biofilm prevention, maturation and dispersal. 
When performing wound debridement, they should always work within the scope of 
practice, and local policy and procedures. 
CLEANSING INFECTED WOUNDS 
Infected wounds should be cleansed thoroughly at each wound dressing change. There 
is a difference between rinsing a wound and cleansing a wound. Therapeutic wound 
cleansing exhibits the following characteristics:23 
n Application of a cleansing solution that has potential to disrupt biofilm and kill planktonic 
bacteria and other organisms (Table 6 outlines the efficacy of various cleansing solutions) 
n Promotion of safety of the wound and the individual 
n Availability in a variety of settings (hospital, clinic and home environment) 
n Irrigation that is performed at an appropriate pound per square inch pressure 
n The periwound being maintained and protected from maceration. 
 
The ideal cleansing agent and the optimal method of wound cleansing has not been 
established conclusively. There may be a role for judicious irrigation with an antiseptic 
solution (see Topical Antimicrobial Therapy). 
 
Surfactants lower the surface tension between the wound bed and the liquid (or between 
two liquids), thereby promoting spread of the liquid across the wound bed and facilitating 
separation of loose, non-viable tissue. This characteristic has been capitalised on in 
the development of several surfactants that are combined with antimicrobials (e.g. 
polyhexamethylene biguanide [PMHB] and undecylenamidopropyl betaine; octenidine 
dihydrochloride and phenoxyethanol; and octenidine and ethylhethylglycerin).23 The use 
of these surfactant-containing antimicrobial cleansers or antimicrobial preservative- 
containing cleansers is useful for disrupting biofilm in the wound.102, 106 
 
There are also newer cleansing agents that are super-oxidised and/or have lower 
concentrations of hypochlorous acid and sodium hypochlorite compared with traditional 
highly toxic preparations that are no longer recommended. These newer solutions are 
purported to disrupt biofilm and kill planktonic bacteria and other organisms while being 
safe for the wound and the individual.103, 104 
 
APPLICATION TO PRACTICE 
Prompt diagnosis and treatment of infection promotes wound healing and minimises the 
impact on the individual, their carer and healthcare systems. Treatment of an infected 
wound should follow a clear and decisive treatment plan. 
Management of comorbidities requires a multidisciplinary team approach. Thorough 
wound hygiene technique and wound debridement will facilitate eradication of microbes, 
either planktonic or biofilm. In the absence of systemic signs of wound infection, local 
treatment with antiseptics, surfactants (in gel or solution form) and antimicrobial 
dressings may be sufficient. 
Post-debridement, topical antimicrobials have been recommended in order to prevent 
PRACTICE POINT 
P  
PRACTICE POINT 
P  
Stop anointing 
wounds and start 
cleansing wounds 
Regular 
reassessment of 
the individual, their 
wounds and the 
management plan 
is essential 
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(or at least delay) attachment of planktonic microbes and to kill any disrupted or 
dispersed biofilm. Table 7 provides a summary of topical options for wound infection. 
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Table 6: Cleansing solutions and gels   
Solution Type Cytotoxicity Effect on biofilm Comments 
Sterile normal saline Isotonic105 None None n Sterile, non-antiseptic solution103 
Sterile water Hypotonic None None n Sterile, non-antiseptic solution103 
Potable tap water Varies in 
content 
Unknown/variable None n Not sterile103 
Polyhexa- 
methylene 
biguanide 
(PHMB) 
Surfactant 
antimicrobial 
Low to none23 Surfactant qualities disrupt biofilm attachments23, 106 n Available in gel and irrigation preparations 
that can be used together or separately 
n Lowers liquid surface tension, allowing 
greater spread and facilitating separation 
of non-viable tissue23 
n Does not promote bacterial resistance23 
Octenidine 
dihydrochloride 
(OCT) 
Surfactant 
antimicrobial 
n In vitro tests show high 
toxicity107 
n Lack of absorption suggests 
no systemic effects107 
n Not shown to disrupt 
healing 
n Prevents formation of new biofilm for at 
least 3 hours108 
n Inhibits planktonic and bacterial biofilm 
growth for up to 72 hours108 
n Available in gel and irrigation preparations 
that can be used together or separately107 
n Lowers liquid surface tension allowing 
greater spread and facilitating separation 
of non-viable tissue108 
Super-oxidised 
with hypochlorous 
acid (HOCL) and 
sodium hypochlorite 
(NaOCL) 
Antiseptic May vary depending on 
concentrations 
n Penetrates biofilm rapidly, killing formations 
from within103 
n Does not promote resistant bacteria 
strains103 
n Purported to provide desloughing and 
antimicrobial activity 
n Available in gel and irrigation preparations 
that can be used together or separately 
Povidone iodine Antiseptic Varies depending on 
concetrations108 
n Inhibits development of new biofilm110 
n Eradicates young biofilm colonies110 
n Significantly reduces mature biofilm 
colonies110 
n Modulates redox potentials and enhances 
angiogenesis, thereby promoting healing111 
n May inhibit excess protease levels in 
chronic wounds111 
 
Table 7: Topical wound infection therapies  
Antimicrobial 
agent 
Type Biofilm efficacy Guidance for use 
Enzyme alginogel Alginate gel with two enzymes: 
n Lactoperoxidase 
n Glucose oxidase 
n Prevents formation of biofilms at concentration 
≤0.5% (w/v)112,113 
n Inhibits growth of established biofilms at 
higher concentrations 
n Does not disrupt biofilm biomass112,113 
n Concentrations of alginate of 3% and 5% depending 
on level of exudate112,113 
Iodine (povidone 
and cadexomer) 
n Solution 
n Impregnated wound dressings 
n Powder and paste 
n Inhibits development of new biofilm110, 114 
n Eradicates young biofilm colonies110, 115 
n Significantly reduces mature biofilm colonies110, 114 
n Contraindicated in individuals sensitive to iodine or 
with thyroid or renal disorders110 
n Contraindicated in those with extensive burns110 
Honey n Medical grade 
n Honey impregnated dressings 
n Inhibits biofilm growth116-118 
n Reduces biofilm colony formation119 
n Inhibits quorum sensing of biofilm, thereby 
reducing ability to proliferate120 
n Select products that have been gamma irradiated119 
n Leptospermum species is more effective than other 
types119 
Silver n Salts (e.g. silver sulphadiazine, 
silver nitrate, silver, sulphate, 
silver CMC) 
n Metallic, e.g. nanocrystalline, 
silver-coated nylon fibres 
n Impregnated wound dressings 
n Denatures existing bacterial biofilm in 
concentrations over 5 µg/ml120 
n Change more frequently in wounds with heavy 
exudate 
n Avoid in individuals with silver sensitivities121 
Ionic silver 
combined 
ethylenediamine- 
tetraacetate 
(EDTA) and 
benzethonium 
chloride 
(BEC) (antibiofilm 
agents) 
n Carboxymethylcellulose 
gelling dressing impregnated 
with ionic silver enhanced 
with EDTA and BEC 
n Combines antibiofilm and antimicrobial 
components that work in synergy to disrupt 
biofilm and expose associated microorganisms 
to the broad-spectrum antimicrobial action of 
ionic silver122 
n Eradicates mature biofilm within 5 days124 
n Prevents biofilm formation124 
n Associated improvement in healing rates125 
n Change more frequently in wounds with heavy 
exudate 
n Avoid in individuals with sensitivities to silver, EDTA 
or BEC123 
Surfactant n Concentrated surfactant gels 
with antimicrobial preservatives 
n Prevents biofilm formation126 
n Increases antibiotic efficacy 
n Eradicates mature biofilm 
n Can be used between and post-debridement to 
prevent re-establishment of biofilm 
n May require daily application for the first few days 
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Topical antimicrobial therapy 
 
he term ‘antimicrobial’ refers to disinfectants, antiseptics and antibiotics.11 
Disinfectants are substances recommended by the manufacturer for 
application to an inanimate object to kill microorganisms and are not 
suitable for internal use. Some disinfectants in lower concentrations are 
used as antiseptics (e.g. sodium hypochlorite). 
TOPICAL  ANTISEPTIC THERAPY 
Antiseptics, also known as skin disinfectants, have a disruptive or biocidal effect 
on bacteria, fungi and/or viruses, depending on the type and concentration of the 
preparation. Antiseptics have multiple sites of antimicrobial action on target cells and 
therefore have a low risk of bacterial resistance. Thus, antiseptics have the potential 
to play an important role in controlling bioburden in wounds while limiting exposure 
to antibiotics and reducing the risk of further antibiotic resistance.127 In the context of 
increasing resistance to antibiotics and the dramatic fall in the number of antibiotics in 
development, restriction on the use of potentially useful antiseptic treatments (e.g. silver) 
is particularly unfortunate. 
Topical antiseptics are non-selective and may be cytotoxic if not delivered to the wound 
in a sustained manner. This means they may kill skin and tissue cells involved in healing 
(e.g. neutrophils, macrophages, keratinocytes, and fibroblasts), thereby impairing the 
healing process. Cytotoxicity may be concentration-dependent,11, 23 as some antiseptics 
in low concentrations are not cytotoxic. Newer-generation antiseptics such as PMHB23 
and octenidine dihydrochloride107 are non-cytotoxic. It is essential to use products with 
a sustained release of antimicrobial agent at concentrations low enough to minimise 
toxicity but still able to destroy or inhibit bacterial and fungal growth. 
Many older antiseptics, including hydrogen peroxide and sodium hypochlorite (e.g. 
EUSOL), are no longer recommended due to the high risk of tissue damage associated 
with their use.128, 129 The exception is use for wound management in low-resource settings, 
where alternative, contemporary antiseptics are not always available. 
In general, most healing wounds do not require the use of antimicrobial therapy. Topical 
antiseptic therapies are recommended for the following:23 
 
n Prevention of infection in individuals who are considered to be at an increased risk 
n Treatment of localised wound infection 
n Local treatment of wound infection in cases of local spreading or systemic wound infection 
using antiseptics, in conjunction with systemic antibiotics. 
 
Duration of use should be individualised and based on regular wound assessment. Many 
clinicians recommend the use of a 2-week challenge with a topical antiseptic, as this 
allows sufficient time for the topical agent to exert a beneficial activity. Usage should be 
reviewed after 2 weeks and the management plan adjusted accordingly.23, 103 
The practice of alternating or rotating topical wound therapies has gained popularity.130 
The premise for this strategy is that suppression of a range of microbials is attained 
through the application of different topical antiseptics in a 2- or 4-week rotation. In 
conjunction with therapeutic cleansing and debridement, alternating the type of antiseptic 
PRACTICE POINT 
P  
PRACTICE POINT 
P  
Use antiseptics at 
the lowest effective 
concentration to 
minimise harm to 
skin and tissue cells 
involved in wound 
healing 
Use a topical 
antiseptic 
for 2 weeks 
before reaching 
conclusions 
regarding its 
effectiveness in 
managing infection 
in a wound 
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applied to the wound may assist in restoration of microbial balance; however, further 
research is required to support this emerging clinical practice.130 
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TOPICAL  ANTIBIOTICS 
The use of topical antibiotics, which contain a low-dose form of antibiotic, may induce 
resistance. Controversy surrounds the use topical anitbiotics and the debate is compounded by 
extensive work on the microbiota of the individual wound. Given the global concern regarding 
antibiotic resistance, use of topical antibiotics for wound management should only be 
considered in infected wounds under very specific circumstances by experienced clinicians.131 
Examples include the use of: 
n Topical metronidazole gel for the treatment of malodour in fungating wounds132 
n Silver sulphadiazine for the treatment of burns and wounds130 
n Mupirocin, a specific topical antibiotic, with no similar compounds used systemically or orally.133 
 
The overall evidence on the efficacy of topical antimicrobials in the management of wounds is 
confusing. Most use is based on laboratory studies rather than clinical research. Of concern is 
the topical use of chloramphenicol ophthalmic ointment used widely by plastic surgeons as a 
post-operative topical surgical prophylaxis.134 
Application of a single dose of topical chloramphenicol to high-risk sutured wounds after 
minor surgery produces a moderate absolute reduction in infection rate that is statistically, 
but not clinically, significant.134 A theoretical, but as yet inconclusively proven, risk of 
chloramphenicol-induced idiosyncratic aplastic anaemia exists with topical ophthalmic 
therapy. A small number of non-fatal cases of suspected topical chloramphenicol-induced 
blood dyscrasia have been reported.135, 136 
 
TOPICAL  ANTIFUNGAL THERAPY 
Topical antifungal therapy can be used in conjunction with good wound care practice (e.g. 
management of wound exudate and other sources of moisture in which fungi proliferate). 
Accurate identification of fungi, although rare, is imperative in selecting appropriate topical and 
systemic treatment.137 The association of fungal infection with a high mortality rate in individuals 
with burns suggests more aggressive management with systemic treatment is appropriate.138, 139 
Wound sampling and molecular analysis suggest that chronic wounds with fungal-associated 
biofilm have unique microbial profiles that require an individualised approach. Antifungal 
therapies (e.g. topical miconazole) may be appropriate; however, poor penetration throughout 
biofilm that contributes to selection of resistant phenotypes is a risk.15, 140 
PRACTICE POINT 
P  
Topical 
antibiotics are 
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for general 
management of 
wound infection 
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Antibiotic therapy 
 
ntibiotics should not be used routinely for the promotion of wound 
healing alone. Judicious use of antibiotics is reserved for wound 
infections confirmed by clinical signs and symptoms and/or 
confirmation by microbiological inquiry. Antibiotics must be used in 
combination with prudent wound management strategies such as 
wound bed preparation (i.e. debridement and therapeutic cleansing).11, 141, 142 
Overuse of antibiotics in humans and livestock, combined with inappropriate antibiotic 
prescribing and patterns of use, has resulted in an increase in antibiotic resistance around 
the world.142, 143 Over time, strains of bacteria that do not succumb to the bactericidal effect of 
antibiotics proliferate and spread throughout communities. As a result, untreatable, multi- 
resistant bacteria are becoming more common and leading to increased mortality rates.143, 144 
Standard wound culturing and advanced technologies (see Investigations to diagnose 
wound infection) do not necessarily provide conclusive information regarding the 
identity of causative bacteria in an infected wound or treatments to which the causative 
microbe will be sensitive.141 Using the wrong antibiotic therapy therefore contributes to 
development of multi-resistant bacteria.144 
Even when an appropriate antibiotic is chosen to manage a wound infection, there are 
treatment challenges. Antibiotics must be able to reach the anatomical site of infection 
in adequate concentrations in order to be effective in destroying infective agents. The 
bioavailability of different antibiotics is variable and dependent on their ability to cross 
tissue barriers and penetrate into bone (e.g. to treat osteomyelitis). The penetration of an 
antibiotic is influenced by absorption, circulation, profusion and plasma protein binding.11, 145 
If uncertain, contact a pharmacist or medical microbiologist for advice. 
ANTIBIOTIC  PROPHYLAXIS 
Prophylaxis is the use of one or more measures to prevent the development of disease 
in individuals who are at high risk of infection. While prophylactic interventions may be 
chemical, biological or mechanical, in the case of surgical wounds, prophylaxis usually 
refers to systemic antibiotic therapy.146 
Antibiotic prophylaxis is most often used to prevent infection in surgical incision sites and 
traumatic wounds where the level of microbial contamination is expected to be significant.54 
PRACTICE POINT 
P  
Systemic 
antibiotics should 
be reserved for 
use only when the 
degree of infection 
is not able to be 
controlled with 
local intervention 
(i.e. topical 
antiseptic and 
debridement at 
every dressing 
change) alone 
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Future developments 
 
ith the ever-increasing resistance of pathogens to antibiotics, there is an 
urgent need to develop new and novel treatments for wound infection. 
At present, a variety of research projects are being undertaken to 
evaluate the role of several methods for treating infection. Some 
of this promising work is outlined below. 
New dressing technologies such as a combination silver dressings incorporating EDTA and 
surfactant BeCL have demonstrated in vitro biofilm disruption with safe topical application.125 
As previously stated the evidence that surfactant has effectiveness for anti-biofilm activity is 
growing. A new concentrated surfactant gel without an antiseptic but containing an antimicrobial 
preservative system has demonstrated biofilm disruption efficacy in an explant model.106 
Multicellular organisms have evolved an arsenal of host-defence molecules,106 including antimicrobial 
peptides (AMPs), aimed at controlling microbial proliferation and at modulating the host’s immune 
response to a variety of biological insults. Antimicrobial peptides may have therapeutic potential 
for the treatment of non-life-threatening skin and other epithelial injuries.147 Two examples include 
talactoferrin, which has been shown to stimulate wound healing, and pexiganan, which was 
developed for the topical treatment of diabetic foot ulcers. 
Bacteriophages and lysins are interventions that use bacterial viruses as antibacterial agents, 
ultimately causing lysis and death of host bacterial cells. These interventions were in popular 
use many years ago, but the development of antibiotics in Western countries rendered their use 
obsolete. However, they were still being developed in countries such as Russia, and are now being 
reinvestigated in the Western world.103 
Therapeutic monoclonal antibodies are available to treat cancer and other diseases. Thus far, none 
have been approved for the treatment of bacterial infection; however, there is considerable ongoing 
research in this field. Antibodies that bind directly to the bacteria usually work by opsonising the 
bacteria for phagocytosis. 
Potentiators of currently used antibiotics, including antibody–antibiotic conjugates, could function 
either by reversing resistance mechanisms in naturally sensitive pathogens or by sensitising 
naturally resistant strains. Much of this work is still in vitro; however, there is much potential for 
future use of these methods.148, 150 
Research is also in progress to explore the use of nanoparticles to deliver target therapeutic agents 
to the wound bed. This may prove useful in managing bacteria and fungi. 
Photodynamic therapy uses photosensitising drug agents, which are selectively absorbed by 
bacteria. These molecules, when exposed to visible light, produce reactive oxygen species lysing 
the bacteria. Research is ongoing into the use of this therapy in inhibiting wound infection. 
Other areas of research involve developments in detection and management of biofilm, including:151 
n Diagnostic tests to detect biofilm at the bedside 
n A clearer understanding of strategies for debridement to disrupt biofilm 
n Treatments that block biofilm formation through disruption of quorum sensing. 
Point-of-care bedside detection of bacteria is also progressing with electronic devices, 
nanoparticles and photodynamic therapy. A device (Moleculight) now exists that illuminates the 
wound with a narrow band of violet light, causing fluorophores in the bacteria to fluoresce, enabling 
capture of an electronic image. Approximately 10 species of bacteria common to chronic wounds 
are detected to a depth of 1.5mm. Initial clinical testing of the devices has proven useful in guiding 
wound debridement. Studies are required to elucidate the clinical significance of findings. 
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Glossary of terms 
 
 
Aerobe: An organism that requires the presence of oxygen in its 
environment in order to survive and multiply.152 
 
Anaerobe: An organism that can survive and multiply in the absence 
of oxygen in its environment. Some bacteria are classified as 
facultative anaerobes as they can sense concentration of oxygen in 
their environment and adjust their metabolism accordingly.152 
 
Antimicrobial: A substance that acts directly on a microbe in a way 
that will either kill the organism or significantly hinder development 
of new colonies. The term incorporates disinfectants, antiseptics 
and antibiotics.91 Antimicrobial therapy may be required when other 
methods of eradication of wound infection are insufficient to manage 
localised wound infection, or when the infection is systemic/spreading. 
 
Antibiotics: A small natural or synthetic molecules that have the 
capacity to destroy or inhibit bacterial growth.153, 154 Antibiotics target 
specific sites within bacterial cells while having no influence on 
human cells, thus they have a low toxicity. They may be administered 
systemically or in topical preparations. Antibiotic resistance is a 
major global health concern.143, 144 
 
Antifungals: Pertaining to a substance that kills fungi or inhibits their 
growth or reproduction. Can be systemic or topical agents. 
 
Antisepsis: The removal of bioburden from living tissue. 
 
Antiseptics: Non-selective agents that are applied topically in order 
to inhibit multiplication of or kill microorganisms. They may have a 
toxic effect on human cells. Development of resistance to antiseptics 
is uncommon. 
 
Aseptic technique: A wound management technique that minimises 
introduction of new pathogenic microorganisms into the wound and 
protects the individual and health professional from cross infection.40, 155 
 
Bacteria: A prokaryotic unicellular organism that may range from 
benign to an invasive pathogen. They may be aerobic, anaerobic, 
motile or immotile. They typically have a cell wall and membrane, 
which become the targets of many antibacterial compounds. 
 
Bactericidal: Agents that kill bacteria through single or multiple 
cellular processes. 
 
Bacteriostatic: Refers to bacterial multiplication/growth that has 
been prevented or inhibited, but may resume if the inhibitory agent is 
removed. 
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Bioburden: Degree or load of microorganisms (e.g. bacteria, virus, 
fungi) that create contamination in a wound.91 The degree of 
bioburden is influenced by the quantity and virulence of microbes. 
 
Cellulitis (also known as spreading infection): Occurs when 
bacteria and/or their products have invaded surrounding tissues 
causing diffuse, acute inflammation and infection of skin or 
subcutaneous tissues.153, 156 
 
Crepitus: A crackling feeling or sound detected on 
palpation of tissues that is due to gas within the tissues 
being released by anaerobic microorganisms.91 Crepitus 
may be associated with presence of Clostridium 
perfringens. 
 
Debridement: The removal of devitalised (non-viable) tissue 
from or adjacent to a wound.154 Debridement also removes 
exudate and bacterial colonies (e.g. biofilm) from the wound 
bed and promotes a stimulatory environment. Methods of 
debridement include autolytic debridement (promotion of 
naturally occurring autolysis), biological debridement (e.g. larval 
therapy), conservative sharp debridement, enzymatic 
debridement, mechanical debridement, low-frequency 
ultrasonic debridement and surgical sharp debridement.157 
 
Delayed wound healing: Wound healing that progresses at 
a slower rate than expected for the individual and the wound. In 
open surgical wounds, the epithelial margin can be expected to 
advance approximately 5mm per week.33 Clean pressure 
injuries can be expected to show signs of healing within 2 
weeks.91 
 
Disinfectant: Substances recommended by the manufacturer for 
application to a non-living object to kill microorganisms. 
 
EDTA: Ethylenediaminetetra-acetic acid 
 
Eschar: A thick, coagulated crust or slough produced by a corrosive 
application, thermal burn or by gangrene.91 
 
Foreign body: Presence in the wound of non-natural bodies that 
may be a result of the wounding process (e.g. gravel, dirt or glass) 
or arise from wound repair (e.g. sutures, staples, orthopaedic 
implants or drains). 
 
Friable: Tissue that bleeds easily, usually due to a high bioburden.91 
 
Fungi: Eukaryotic, filamentous (multicellular fungal hyphae) or 
budding (single cellular yeast) or dimorphic organism that is a 
member of the kingdom Fungi. This includes a large number of 
ubiquitous organisms, some of which are potential pathogens. 
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Granulation tissue: The pink/red, moist, shiny tissue that glistens 
and is composed of new blood vessels, connective tissue, 
fibroblasts, and inflammatory cells that fills an open wound when 
it begins to heal. It typically appears deep pink or red with an 
irregular, granular surface.153 
 
Induration: Hardening of the skin and subcutaneous tissues 
around a wound91 due to inflammation, which may be 
secondary to infection. 
 
Lymphangitis: Inflammation of lymph vessels, seen as red 
skin streaks running proximally from a site of infection. 
 
Necrotic tissue/necrosis: Dead (devitalised) tissue that 
is dark in colour and comprised of dehydrated, dead 
tissue cells. Necrotic tissue acts as a barrier to healing by 
preventing complete tissue repair and promoting microbial 
colonisation.158 
 
Periwound: The area immediately adjacent to the wound edge 
and extending out as far as the tissue colour and consistency 
changes extend. 
 
Persister cells: A cell that resists a generally toxic level of a 
drug (e.g. an antibiotic) or intervention although the organism 
is generally not genetically resistant to the treatment.159 
 
Phenotype: Observable characteristics or traits of a living 
organism that arise from its genetic make-up. 
 
pH: A measure on a scale from 0 to 14 of acidity or alkalinity, 
with 7 being neutral, greater than 7 being more alkaline and 
less than 7 being more acidic.91 
 
Phagocytosis: The process by which certain living cells 
(phagocytes) engulf or ingest other cells or particles. 
 
Planktonic bacteria: Planktonic cells are bacteria growing in 
a free-floating environment, meaning they are not part of a 
structured community or biofilm.47 
 
Pocketing: This occurs when granulation tissue does not grow in a 
uniform manner across the entire wound or when healing does not 
progress from the bottom up to the top of the wound. Pockets can 
harbour bacteria.91 
 
Potable water: Water that is fit for consumption by humans and 
animals.91 
 
Prophylaxis: The use of one or more measures to prevent the 
development of disease in susceptible hosts with high risk of 
infection. Prophylactic interventions can be chemical, 
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biological or mechanical, but in the case of surgical 
wounds are usually systemic antibiotics.146 
 
Pyrexia: Abnormal elevation of the body temperature, 
or a febrile condition.160 
 
Quorum sensing: A density-dependent cell-to-
cell communication system through small 
molecules that regulates the gene expressions 
and behaviour of bacteria within the community.47, 
161
 
 
Resistance/tolerance: Antimicrobial 
resistance refers to a specific mechanism of 
drug resistance; for example, 
production of a beta-lactamase enzyme that confers 
resistance to beta-lactam antibiotics (i.e. penicillin). 
Tolerance refers 
to the decreased susceptibility and enhanced 
tolerance to antimicrobials in a non-specific 
manner.143 Biofilms have enhanced tolerance to 
antimicrobials because of reduced penetration and 
metabolism within the biofilm. 
 
Sepsis: Sepsis is a life-threatening complication, 
characterised by a range of signs and symptoms, 
arising from an overwhelming host response to 
infection. Signs and symptoms of sepsis include 
excessive pain; confusion or disorientation; shortness 
of breath; shivering, fever or very cold temperature; 
high heart rate; and clamminess. It may also include 
more localised signs of infection (e.g. diarrhoea, sore 
throat, respiratory symptoms).162 
 
Sequester: To detach or separate abnormally a small 
portion from the whole.160 
 
Slough: Soft avascular or non-viable tissue. The 
colour and thickness varies depending on hydration of 
the tissue and may be obscuring underlying structures 
or tunnelling. 
 
Surfactant: Surfactant is a complex naturally occurring 
substance made of six lipids (fats) and four proteins 
that is produced in 
the lungs. It can also be manufactured synthetically. Surfactant 
reduces the surface tension of fluid in the lungs and helps make 
the small air sacs in the lungs (alveoli) more stable. 
 
Wound culture: A sample of tissue or fluid taken from the 
wound bed and placed in a sterile container for transportation 
to the laboratory. In the laboratory, the sample is placed in a 
substance that promotes growth of organisms and the type and 
quantity of organisms that grow are assessed by microscopy. 
Wound cultures are used to determine the type and quantity of 
microorganisms in a wound.163 
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Appendix 1: Methodology 
 
 
 
Literature search 
This edition of Wound Infection in Clinical Practice is underpinned by a targeted literature search 
to identify relevant research published since the previous edition in 2008. Searches were 
conducted in four major medical databases: Medline, Embase, CINAHL and the Cochrane 
Library. Searches were made for research in nine broad fields related to wound infection: 
diagnosis, systematic/holistic management, topical management, antibiotic therapy, emerging 
research, terminology, biofilm management, wound cleansing and terminology. Search terms 
related to wound infection were combined with terms specific to each broad field. The search 
was limited to articles published in database-listed journals since 2008 in English language. 
After identification, references were screened for their relevance to the project and grouped 
according to the wound infection-related topics for which they provided evidence. References 
considered to provide high-quality research and/or unique information were reviewed more 
thoroughly by the IWII experts. Approximately 300 references were identified and reviewed as 
part of the literature search. Additional references known to the experts were added to those 
identified in the literature search, including seminal papers from pre-2008. 
Delphi process 
In order to make updates to clinical topics for which there is limited or no scientific evidence, the 
IWII expert group engaged in a Delphi process. The process was designed to elicit consensus 
from the expert panel through an iterative process involving a number of voting rounds. A 
sub-group of experts developed the specific statements that were posed to the expert panel 
for discussion and agreement. These statements emerged from the literature review and early 
development of this document. The broad areas covered by the statements for consensus voting 
related to: 
n Definitions and terminology 
n Clinical indicators of a chronic wound 
n Clinical indicators of the presence of biofilm in a wound 
n Update and presentation of the wound infection continuum 
n Signs and symptoms of wound infection. 
The Delphi process was iterative, with three rounds of voting required to reach agreement on the 
statements on which the expert panel voted. The statements were presented to the expert panel 
with a brief discussion presenting the background of each issue. This provided every member 
of the panel with sufficient baseline knowledge to form an opinion. As with a typical Delphi 
process,164-166 the expert panellists voted their level of agreement with each presented statement, 
based on the background discussion and their extensive expertise in the field. A nine-point Likert 
scale, labelled from ‘strongly agree’ through to ‘strongly disagree’, was used for responses. After 
each voting round, the level of agreement of the entire voting panel was calculated to determine 
the level of consensus. 
For each statement, the expert panel members were required to provide qualitative comments 
as a rationale for their level of agreement. As with a typical Delphi process,164-166 these comments 
were moderated and fed back to the group in subsequent voting rounds. Panel member 
comments accumulated over the three voting rounds, building up a reasoning summary that 
presented the opinion in agreement and/or disagreement of each statement. 
Votes were cast using a custom designed web interface167 and the level of consensus was 
calculated automatically by a computer script167 based on previously reported methodology167 
that has been validated in the wound care context.169, 170Due to the nature of the project, 
participant anonymity was not possible. However, individual votes and comments provided in 
feedback remained anonymous to both the moderator and other participants. 
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